CLINICAL_TRIALS
trial_result
· 2014-10-06
Clinical Trial Update: Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Summary
A completed observational safety study of ecallantide (KALBITOR) in treating acute hereditary angioedema attacks; results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Status: COMPLETED | Results posted: 2014-10-06